Physician profile
Nicholas Donas
NPI 1861567174
$2,027.71
in general payments reported to CMS, 2019-2025
21 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $197 · 2021: $188 · 2022: $371 · 2023: $256 · 2024: $315 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $552.38 | 2019-2025 | Argos, Rocklatan, Clareon |
| Bausch & Lomb Americas INC. | $273.35 | 2022-2025 | Miebo, Envista Mx60 Iol, Vyzulta |
| Sun Pharmaceutical Industries INC. | $265.02 | 2019-2025 | Cequa |
| Abbvie INC. | $166.66 | 2022-2025 | Lumigan, Alphagan P |
| Oyster Point Pharma, INC. | $96.85 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $80.98 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $75.00 | 2019-2021 | |
| Amgen INC. | $68.12 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $67.92 | 2021 | |
| Ocular Therapeutix, INC. | $59.30 | 2024 | Dextenza |
| Harrow Eye, LLC | $50.01 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $45.80 | 2019-2021 | |
| Dompe US, INC. | $39.37 | 2021-2025 | Oxervate |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Astellas Pharma US INC | $28.05 | 2025 | Izervay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $27.19 | 2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Shire North American Group INC | $24.93 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.56 | 2019 | |
| Thea Pharma INC. | $17.55 | 2023 | |
| Allergan, INC. | $17.42 | 2021 | |
| Horizon Therapeutics Plc | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Donas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.